These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23299550)

  • 1. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9.
    Jiang M; Huang O; Zhang X; Xie Z; Shen A; Liu H; Geng M; Shen K
    Molecules; 2013 Jan; 18(1):701-20. PubMed ID: 23299550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
    Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
    PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
    Wu C; Luo J
    Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
    Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Cheng R; Liu YJ; Cui JW; Yang M; Liu XL; Li P; Wang Z; Zhu LZ; Lu SY; Zou L; Wu XQ; Li YX; Zhou Y; Fang ZY; Wei W
    Oncotarget; 2017 May; 8(18):30252-30264. PubMed ID: 28415819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells.
    Huang O; Xie Z; Zhang W; Lou Y; Mao Y; Liu H; Jiang M; Shen K
    Oncol Rep; 2014 Aug; 32(2):627-34. PubMed ID: 24919713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
    Li Z; Yu D; Li H; Lv Y; Li S
    Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
    Lu PW; Li L; Wang F; Gu YT
    J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
    Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS
    Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
    Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
    Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.
    Chen J; Wang W; Wang H; Liu X; Guo X
    Drug Discov Ther; 2014 Feb; 8(1):33-41. PubMed ID: 24647156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin Rescues Doxorubicin Responsiveness via Regulating Aurora a Signaling Network in Breast Cancer Cells.
    Biswas S; Mahapatra E; Ghosh A; Das S; Roy M; Mukherjee S
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):957-970. PubMed ID: 33773562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism.
    Bava SV; Sreekanth CN; Thulasidasan AK; Anto NP; Cheriyan VT; Puliyappadamba VT; Menon SG; Ravichandran SD; Anto RJ
    Int J Biochem Cell Biol; 2011 Mar; 43(3):331-41. PubMed ID: 20883815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.
    Zhang X; Mu X; Huang O; Xie Z; Jiang M; Geng M; Shen K
    PLoS One; 2013; 8(8):e72053. PubMed ID: 23991038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
    Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
    Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.
    Nehra R; Riggins RB; Shajahan AN; Zwart A; Crawford AC; Clarke R
    FASEB J; 2010 Jun; 24(6):2040-55. PubMed ID: 20154269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells.
    Coker-Gurkan A; Celik M; Ugur M; Arisan ED; Obakan-Yerlikaya P; Durdu ZB; Palavan-Unsal N
    Amino Acids; 2018 Aug; 50(8):1045-1069. PubMed ID: 29770869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.